Aflibercept remains superior to bevacizumab after 2 years of treating patients with poor baseline visual acuity (VA) caused by diabetic macular edema (DME), but it loses its edge over ranibizumab, researchers said.
As a physician passionate about treating and helping patients with retinal disease, I continuously seek out and study new treatment modalities. It can be a very scary time for patients when faced with retinal conditions, such as macular degeneration, retinal detachments, and diabetic macular edema (DME).
Sabin Dang, MD, didn’t have as clear cut of a journey to the ophthalmic world as many would expect. While today he spends his working hours improving visual outcomes of patients at Ophthalmic Consultants of Boston, a few years ago you would have found him creating coding software in his IT consulting company to help businesses grow.
Significant in her history was blunt trauma to the left eye approximately six years earlier. The nature of this was described as, “…getting a finger poked in my eye.” There were no contributory elements to her medical, family, or social histories.
We all know the typical algorithm for our patients having diabetes: Maintain healthy blood sugar and pressure control, get annual dilated eye examinations, and receive laser or anti-VEGF therapy if and when they develop vision-threatening diabetic retinopathy (DR).
It’s been a busy week for ophthalmology research and news after both the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle and the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in New Orleans.